Research programme: histone deacetylase inhibitors - BioMarin

Drug Profile

Research programme: histone deacetylase inhibitors - BioMarin

Alternative Names: BMN-290; HDAC inhibitors - BioMarin

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Repligen Corporation
  • Developer BioMarin Pharmaceutical; Repligen Corporation
  • Class Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Friedreich's ataxia
  • No development reported Huntington's disease
  • Discontinued Cognition disorders; Spinal muscular atrophy

Most Recent Events

  • 26 Oct 2017 Preclinical trials in Friedreich's ataxia in USA (PO)
  • 26 Oct 2017 BioMarin announces intention to submit IND for BMN 290 for Freidriech's ataxia in the second half of 2018
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Friedreich's ataxia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top